Know the Risk. Personalize the Choice.
GENETIC INSIGHTS FOR RADIATION THERAPY DECISIONS
PROSTOX® predicts late GU adverse events (AEs) after specific RT regimens by analyzing inherited microRNA-associated genetic variants before prostate cancer treatment starts. Identifying whether one treatment is safer than another helps to select the best treatment approach.
The Two PROSTOX Tests:
PROSTOX Ultra
For patients considering SBRT
PROSTOX Standard
For patients considering CFRT/MHFRT
Request a meeting with our Medical Team
Clinically Validated. Backed by Evidence.
93% of patients can safely receive external beam radiation therapy without being at high risk for developing late genitourinary adverse events.1
NEW DATA BEING PRESENTED AT ASTRO 2026
Featured Scientific Presentation
Tuesday, September 29, 3:45 PM – 3:55 PM ET | Room 210 | Presented by Amar Kishan, MD, UCLA Radiation Oncology
Germline Biomarkers for Late Genitourinary Adverse Events after Radiotherapy for Prostate Cancer: Validation in Multiple Prospective Trials
Other Scientific Presentations
Presented by Joanne Weidhaas, MD, PhD, UCLA Radiation Oncology
Germline microRNA-Based Signatures to Predict Radiation Treatment Toxicity
mRNA and miRNA Expression Differences Between High- and Low-Risk PROSTOX Patients
Germline Biomarker Predicts Adverse Events Following SBRT to the Prostate Fossa After Radical Prostatectomy
Request a meeting with the MiraDx Medical Team at ASTRO 2026
Complete the form and our team will contact you.
Or ready to order PROSTOX for your patients now? Get Started